Vor Biopharma (VOR) has shared an update.
Vor Biopharma Inc. has expanded its Board of Directors with the appointment of Fouad Namouni, M.D., as an independent Class II director. Dr. Namouni, with over two decades of experience in oncology and cancer immunotherapy, adds significant expertise to the board. His past leadership roles at Bristol Myers Squibb and Blueprint Medicines Corporation underscore his qualifications. Dr. Namouni will also serve on the Nominating and Corporate Governance Committee and will receive the company’s standard compensation for non-employee directors.
For detailed information about VOR stock, go to TipRanks’ Stock Analysis page.
